Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas (NCT06422806)

🧪 Interventions in This Study

• Doxorubicin (DRUG)
• Pembrolizumab (BIOLOGICAL)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patient must be \>= 18 years of age
2. Patient must have a confirmed histopathologic diagnosis of dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. Because UPS can sometimes exist in a spectrum among related diagnoses, the following additional diagnostic will be allowed, but not limited to:
3. Pleomorphic sarcoma with inflammation or with limited areas of differentiation
4. Pleomorphic sarcoma with giant cells
5. Malignant fibrous histiocytoma (including storiform-pleomorphic and inflammatory subtypes)
6. Myxofibrosarcoma
7. Poorly differentiated sarcoma not otherwise specified (NOS)
8. Undifferentiated spindle cell sarcoma
9. Poorly differentiated spindle cell sarcoma NOS Any of these subtypes may have areas of focal myogenic differentiation
10. Patient must have metastatic or unresectable sarcoma
11. Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria:
12. Has achieved menarche at some point

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (257 Sites)

Showing the first 25 of 257 sites.

• Mayo Clinic Hospital in Arizona — Phoenix, Arizona
• Banner University Medical Center - Tucson — Tucson, Arizona
• University of Arizona Cancer Center-North Campus — Tucson, Arizona
• Kaiser Permanente Dublin — Dublin, California
• Kaiser Permanente-Fremont — Fremont, California
• Kaiser Permanente Fresno Orchard Plaza — Fresno, California
• Kaiser Permanente-Fresno — Fresno, California
• UC San Diego Moores Cancer Center — La Jolla, California
• Keck Medicine of USC Koreatown — Los Angeles, California
• Los Angeles General Medical Center — Los Angeles, California
• USC / Norris Comprehensive Cancer Center — Los Angeles, California
• Cedars-Sinai Medical Center — Los Angeles, California
• Kaiser Permanente- Modesto MOB II — Modesto, California
• Kaiser Permanente-Modesto — Modesto, California
• USC Norris Oncology/Hematology-Newport Beach — Newport Beach, California
• Kaiser Permanente-Oakland — Oakland, California
• Stanford Cancer Institute Palo Alto — Palo Alto, California
• VA Palo Alto Health Care System — Palo Alto, California
• Huntington Memorial Hospital — Pasadena, California
• Kaiser Permanente-Roseville — Roseville, California
• Kaiser Permanente Downtown Commons — Sacramento, California
• Kaiser Permanente-South Sacramento — Sacramento, California
• Kaiser Permanente-San Francisco — San Francisco, California
• UCSF Medical Center-Mission Bay — San Francisco, California
• Kaiser Permanente-Santa Teresa-San Jose — San Jose, California

📞 Contact the Study Coordinator

Phone: (855) 776-0015

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Dedifferentiated Liposarcoma

• Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma — Los Angeles, California

Explore by condition: All Metastatic Dedifferentiated Liposarcoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.